期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

转移性结直肠癌三线治疗的研究进展 被引量：1

The third-line treatment of metastatic colorectal cancer
暂未订购
导出
摘要 理想的三线治疗方案应该能够缓解肿瘤的相关症状,提高患者的生活质量。目前转移性结直肠癌的三线治疗尚无标准方案,但已引起关注,本文对相关Ⅱ、Ⅲ期临床研究进行简要评述。 Ideal third-line treatment for patients should be able to alleviate tumor-related symptoms and improve quality of life.The third-line treatment of the metastatic colorectal cancer has no standard treatment options.This article briefly reviews Ⅱ,Ⅲ phase clinical studies.
作者 徐玲 刘云鹏
机构地区 中国医科大学附属第一医院肿瘤内科
出处 《临床肿瘤学杂志》 CAS 2011年第5期472-474,共3页 Chinese Clinical Oncology
基金 国家自然科学基金资助项目(30770993) 高等学校博士学科点专项科研基金资助项目(20102104120008) 中国医科大学附属第一医院科学研究基金资助项目(fsfh1003)
关键词 结直肠癌 治疗 Colorectal cancer Therapy
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献20

  • 1Kim GP, Sargent DJ, Mahoney MR, et al. Phase Ⅲ noninfefiori- ty trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced eolorectal carcinoma previ- ously treated with fluorouracil : N9841 [J]. J Clin Oncol, 2009, 27(17) : 2848 -2854.
  • 2Kemeny N, Garay CA, Gurtler J, et al. Randomized multicenter phase Ⅱ trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracilfleucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer[J]. J Clin Oncol, 2004, 22(23): 4753-4761.
  • 3Gholam D, Giacchetti S, Brezault-Bonnet C, et al. Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouraeil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer[J]. Oncologist, 2006, 11(10): 1072-1080.
  • 4沈康,黄新恩,戴爱娣,钱芝英,孙蔚莉.CPT-11联合草酸铂、5-Fu方案二、三线治疗晚期大肠癌的临床研究[J].肿瘤基础与临床,2008,21(4):340-342. 被引量：1
  • 5Bitossi R, Sculli CM, Tampellini M, et al. Gemcitabine and pro- tracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients[J]. Anticancer Res, 2008, 28 (5B) : 3055 -3060.
  • 6李慧,秦叔逵,华海清,何泽明,刘秀峰,王琳,陈映霞.吉西他滨联合氟尿嘧啶类药物治疗耐药性晚期结直肠癌的临床观察[J].临床肿瘤学杂志,2010,15(9):811-814. 被引量：3
  • 7Ardavanis AS, Ioannidis GN, Orphanos GS, et al. Salvage treatment with single-agent capecitabine in patients with heavily pre treated advanced colorectal cancer [ J]. Anticancer Res, 2006, 26(2B) : 1669 - 1672.
  • 8Jeung HC, Rha SY, Cho BC, et al. A phase Ⅱ trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan-and oxaliplatin-containing regimens[J]. Br J Cancer, 2006, 95(12) : 1637 - 1641.
  • 9Yokoyama T, Tokuhara H, Egawa T, et al. The efficacy of S-1 monotherapy as a 2nd/3rd-line therapy for unresectable recurrent colon cancer: Kanagawa conference of clinical oncology (KCCO) [J]. Gan To Kagaku Ryoho, 2009, 36(10) : 1667 -1670.
  • 10Lee DJ, Lee J, Lee HY, et al. Salvage S-1 monotherapy in meta-static colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy[ J ]. Med Oncol, 2010 : [ 2010-12- 10 ]. http ://www. ncbi. nlm. nih. gov/pubmed/21116875.

二级参考文献31

  • 1李玉升,张弘刚,黄镜,迟.依荷芭丽,杨林,宋岩,张雯,胡兴胜,袁芃,王金万.含有CPT-11的联合化疗方案治疗晚期胃肠道癌26例临床观察[J].临床肿瘤学杂志,2004,9(3):265-266. 被引量：15
  • 2游晓文,徐宁红,陈尚忠.格拉司琼预防化疗所致消化道反应的临床疗效分析[J].西南军医,2007,9(1):39-40. 被引量：1
  • 3Folprecht G, Lutz M P, Schoffski P,et al. Cetuximab and irinotecan/5-fluorouracil/folinic acidis a safe combination for the first line treatment of patients with epidermalgrowth factor receptor expressing metastatic colorectal carcinoma[J]. Ann Oncol 2006, 17(3) : 450-456.
  • 4Tabernero J, Pfeiffer P, Cervantes A. Administration of cetux imab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more conveient alternative to weekly ad ministration[J]. Oncologist, 2008,13(2) :113-119.
  • 5Jimenez P, Gomez G, Rodriguez B, et al. Acute acneiform eruption secondary to cetuximab with good response to metronidazole [J]. Actas Dermosifiliogr, 2007,98 (9) : 648-653.
  • 6Lenz H J,Van Cutsem E, Khambata F S, et al. Multicenter phase Ⅱ and translational study of eetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluropyrimidines[J]. J Clin Oncol,2006,24(30) :4914-4921.
  • 7Chung K Y, Shia J, Kemeny N E, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry [J]. J Clin Oncol,2005,23(9) :1803-1810.
  • 8Aurelien R, Valerie B, Gerard M,et al. KRAS mutation signa ture in colorectal tumors significantly overlaps with the cetux imab response signature[J]. J Clin Oncol,2008,26(13) : 2228-2230.
  • 9Jemal A,Siegel R,Ward E,at al.Cancer statistics,2007[J].CA Cancer J Clin,2007,57(1):43-66.
  • 10Madajewicz S,Hentschel P,Burns P,et al.Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies[J].J Clin Oncol,2000,18(20):3553-3557.

共引文献8

同被引文献6

引证文献1

二级引证文献1

临床肿瘤学杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部